GlassScriptPhysician profile
Samuel A Berger
NPI 1225215031
$3,252.38
in general payments reported to CMS, 2019-2025
27 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $170 · 2021: $604 · 2022: $339 · 2023: $659 · 2024: $493 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $514.71 | 2019-2025 | Rocklatan, Eysuvis, Clareon |
| Sun Pharmaceutical Industries INC. | $472.98 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $262.46 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $251.19 | 2019-2023 | |
| Abbvie INC. | $235.47 | 2023-2024 | Durysta |
| Bausch & Lomb Americas INC. | $168.95 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Mallinckrodt Enterprises LLC | $164.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $135.08 | 2021-2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $126.95 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $121.04 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.13 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $100.38 | 2019-2021 | |
| Horizon Therapeutics Plc | $59.54 | 2021-2023 | Tepezza |
| Biotissue Holdings INC. | $58.14 | 2021-2023 | |
| Coopervision INC. | $55.69 | 2021-2024 | Myday Contact Lens |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $52.34 | 2021-2024 | Oxervate |
| Ocular Therapeutix, INC. | $47.44 | 2023-2025 | Dextenza |
| Shire North American Group INC | $45.91 | 2019 | |
| Tearlab Corp | $42.90 | 2023 | Tearlab Osmolarity System |
| Rayner Intraocular Lenses Limited | $40.66 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $38.63 | 2020 | |
| Genzyme Corporation | $36.31 | 2019 | |
| Harrow Eye, LLC | $35.52 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $33.30 | 2019-2023 | Acuvue |
| Rxsight INC | $23.16 | 2022 | |
| Thea Pharma INC. | $12.87 | 2023 | |
| Allergan, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.